knowledge -WSS

knowledge

author：knowledge 2025-09-27 22:46:15 - browse：56541

Eli Lilly headquarters in Indianapolis – pharmaceutical coverage from STAT — Darron Cummings/AP

The blockbuster weight loss and diabetes drug sold by Eli Lilly also appears to improve fatty liver disease, according to early clinical trial data the pharmaceutical company released Tuesday.

Eli Lilly reported during its fourth-quarter earnings call that tirzepatide, which is sold commercially as Mounjaro or Zepbound, succeeded in a Phase 2 test as a treatment for the liver disease MASH. Around 74% of adults in the trial taking the drug were free of MASH after 52 weeks, compared to approximately 13% of the placebo group.

MASH, formerly known as NASH, is a liver disease characterized by excess fat and inflammation. The chronic inflammation can also lead to liver scarring, or fibrosis.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Hollywood unions extend contract negotiations for actors
Next article： Surge of respiratory disease in China has likely explanation

WSS

A daunting task: navigating dual Medicare, Medicaid eligibility

Novel spinal cord stimulator treats paralysis without surgery

How a small hospital in rural Puerto Rico survived Hurricane Maria

Can gargling with Listerine treat gonorrhea of the mouth?

As billionaires fund anti

AI for drug discovery: Experts on separating hype from reality

focus

knowledge

leisure time

Tori Bowie and the unacceptable rates of Black maternal death

Has Bernie Sanders reached the limit of his pharma bullying effort?

Hepatitis C has a cure — but many Americans still lack access to it

Readout Newsletter: Bayer study halts, Carmot to IPO, and more

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Why medical students are struggling with mental health

In age of alternative facts, a scholarly course on calling out crap

GSK’s asthma push continues as drug succeeds in Phase 3 trials

Activists slam private health insurers over coverage restrictions

In key trial, Verve's treatment lowers cholesterol levels in patients

focus

Class action alleges UnitedHealth concealed DOJ probe

Does good food count as health care? Study aims to find out

Readout Newsletter: The latest at Gilead, Catalent, and the NIH

Weight loss drug costs may need more research, senator suggests

Has Bernie Sanders reached the limit of his pharma bullying effort?

Readout Newsletter: Bayer study halts, Carmot to IPO, and more

explore

focus

entertainment

explore